$482,000 / year

Greed lives.

 

there is always a way to justify a high price
1) not that many patients
2) probably not used first line
3) cost of inhibitors is huge

 

Don't forget that this along with Ocrevus will have the burden of making up for lost revenue coming out of oncology........

 

1) true
2) false
3) very true

 

50% less than competitors! You can't single out one drug/manufacturer. Pricing is a healthcare issue (not just a Pharma/Biotech/GNE) issue.

 

Haters gonna hate.

 

You apparently know half of the truth. It’s nearly half of the current treatment.